ESR1 and colorectal cancer: In colorectal cancer, concordance of KRAS mutations vary between 86.4% and 92% [27], estrogen receptor 1 (ESR1) mutation in metastatic breast cancer is concordant in 74.3% of patients [28] and actionable EGFR in NSCLC was reported to be concordant in 79% of patients [29].